ArticleClinical case reports2022
New-onset atypical fulminant type 1 diabetes after COVID-19 vaccination: A case report.
Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- SARS-CoV-2 infection and COVID-19 vaccination and the risk for new-onset type 1 diabetes: a register-based population study in Sweden.Diabetologia · 2026Article
- Review
- New-onset Fulminant Type 1 Diabetes Following COVID-19 Vaccination.Internal medicine (Tokyo, Japan) · 2025Article
- Fulminant Type 1 Diabetes Mellitus With Concomitant Coxsackievirus B6 Antibody Elevation and RNA-Based COVID-19 Vaccination: A Case Report and Review of the Literature.Clinical case reports · 2025Article
- Review
- New-Onset Fulminant Type 1 Diabetes After SARS-CoV-2 Infection.Diabetes care · 2023Article
- New-Onset Fulminant Type 1 Diabetes Following SARS-CoV-2 Protein Subunit Vaccine: A Case Report and Literature Review.Journal of Korean medical science · 2023Review
- Case report: A case of fulminant type 1 diabetes mellitus after COVID-19 vaccination during treatment of advanced gastric cancer: pitfall in managing immune-related adverse events.Frontiers in oncology · 2023Article
- Case report: Fulminant type 1 diabetes following paucisymptomatic SARS-CoV-2 infection during late pregnancy.Frontiers in endocrinology · 2023Article
- New-onset atypical fulminant type 1 diabetes after COVID-19 vaccination: A case report.Clinical case reports · 2022Article
- Type 1 Diabetes Mellitus Caused by COVID-19 mRNA Vaccination: A Case Report and Literature Review of 17 Published Cases.AACE clinical case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse reactions, including the onset of diabetes, after coronavirus disease 2019 (COVID-19) vaccination have been reported. Herein, we report a case of a man who developed anti-glutamic acid decarboxylase (GAD) antibody-positive fulminant type 1 diabetes 15 weeks after COVID-19 vaccination, atypical of the previously reported anti-GAD antibody-negative cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.